Regis Healthcare Limited (ASX: REG), has unveiled its FY23 full-year results, showing substantial growth in key financial indicators, including revenues of $780.6 million, representing an 8% increase compared to the previous fiscal year.
The underlying EBITDA also experienced an uptick, reaching $83.3 million, an increase of 7% over the same period last year. Notably, NPATA increased by 631% to reach $28.5 million, though a statutory net loss of $28.5m after tax was recorded, influenced by non-cash bed license amortisation.
Regis reported a notable decrease in net debt, reaching $6.0 million, reflecting a 94% decline from the previous fiscal year. A significant operational achievement was an average occupancy of 91.5%, a noteworthy improvement on last year’s 89.8%.
Despite facing challenges such as workforce shortages, visa delays, and pandemic-related impacts, Regis’ Managing Director and CEO, Dr Linda Mellors, flagged in a market release the company’s substantial growth across various metrics, including revenue, occupancy, and earnings.
At the time of writing the share price was $2.40, representing a 14.29% increase over the last 12 months.
The Board of Directors resolved to pay a final dividend of 7.48 cents per ordinary share
totalling $22.5 million (50% franked) for the year ended 30 June 2023, payable on
27 September 2023.
